Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS)
Objective.— To evaluate and compare healthcare resource use and related costs in chronic migraine and episodic migraine in the USA and Canada.
Background.— Migraine is a common neurological disorder that produces substantial disability for sufferers around the world. Several studies have quantified overall costs associated with migraine in general, with recent estimates ranging from $581 to $7089 per year. Although prior studies have characterized the clinical and humanistic burden of chronic migraine relative to episodic migraine, to the best of our knowledge only 1 previous study has compared chronic migraine and episodic migraine healthcare costs. The purpose of this study was to quantify and compare the direct medical costs of chronic migraine and episodic migraine using medical resource use data collected as part of the International Burden of Migraine Study.
Methods.— Cross‐sectional data were collected from respondents in 10 countries via a Web‐based survey. Respondents were classified as chronic migraine (≥15 headache days/month) or episodic migraine (<15 headache days/month). Data collection included socio‐demographic and clinical characteristics and medical resource use for headache (clinician and emergency department visits and hospitalizations over the preceding 3 months and medications over the preceding 4 weeks). Unit cost data were collected outside of the Web‐based survey using publicly available sources and then applied to resource use profiles. Cost estimates are presented in 2010 US and Canadian dollars.
Results.— In this manuscript, the analysis included data from respondents with migraine in the USA (N = 1204) and Canada (N = 681). The most common medical services utilized by all respondents included headache‐specific medication, healthcare provider visits, emergency department visits, and diagnostic testing. In the USA, approximately one‐quarter (26.2%) of chronic migraine participants vs 13.9% of episodic migraine participants reported visiting a primary care physician in the preceding 3 months (P < .001). In Canada, one‐half (48.2%) of chronic migraine participants had a primary care physician visit, compared with 12.3% of episodic migraine subjects (P < .0001). Total mean headache‐related costs for participants with chronic migraine in the USA were $1036 (±$1334) over 3 months compared to $383 (±807, P < .001) for persons with episodic migraine. In Canada, total mean headache‐related costs among chronic migraine subjects were $471 (±1022) compared to $172 (±920, P < .001) for episodic migraine subjects.
Conclusions.— Chronic migraine was associated with higher medical resource use and total costs compared to episodic migraine. Therapies that reduce headache frequency could become important approaches for containing or reducing headache‐related medical costs.
Document Type: Research Article
Affiliations: From United BioSource Corporation, Dorval, QC, Canada (M. Stokes); and Bethesda, MD, USA (T.K. Wilcox and I. Proskorovsky); University of Calgary, Calgary, AB, Canada (W.J. Becker); Montefiore Headache Center and the Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA (R.B. Lipton and D.C. Buse); University of Washington, Seattle, WA, USA (S.D. Sullivan); Allergan Canada, Markham, ON, Canada (L. Wells); Allergan, Inc., Irvine, CA, USA (A. Manack and S.F. Varon); Gladstone Headache Clinic, Toronto, ON, Canada (J. Gladstone); Headache Group, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA (P.J. Goadsby); The Neurology Center, Encinitas, CA, USA (A.M. Blumenfeld).
Publication date: July 1, 2011